cell-mediated immunity

(redirected from Cell immunity)
Also found in: Dictionary, Medical.

cell-mediated immunity

[¦sel ¦mē·dē‚ād·əd i′myü·nəd·ē]
(immunology)
Immune responses produced by the activities of T cells rather than by immunoglobulins.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Joyee et al., "NK cells promote type 1 T cell immunity through modulating the function of dendritic cells during intracellular bacterial infection," The Journal of Immunology, vol.
Lindsay et al., "Protective T cell immunity in mice following proteinTLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets," The Journal of Clinical Investigation, vol.
Annual Vaccination Against Influenza Virus Hampers Development of Virus-Specific CD8 T Cell Immunity in Children.
Another major lesson for HIV immunology is what measures of possible immune correlates of protective T cell immunity should be employed in future vaccine trials.
population had some immunity against the pandemic strain, thanks to T cell immunity.
This suggests hyperglycaemia or metabolic syndrome in Type 2 could compromise T cell immunity."
The peer-reviewed paper entitled "Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory," describes the immune response induced from direct injection of Intensity's lead product candidate, INT230-6, into subcutaneously implanted murine colon and orthotopic breast tumors.
tularensis infection and implicate IL17 in the regulation of Th1 cell immunity against Francisella tularensis [84, 85].
In this phase I trial, RNA vaccines encoding for four tumor antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) were well tolerated and elicited dose-dependent release of early IFN[alha] and CXCL10 and de novo T cell immunity against vaccine antigens [71,72].
According to the company, T cell immunity against cytomegalovirus (CMV) is a factor in controlling viral latency and susceptibility to CMV disease, which can affect individuals with weaknesses in their T cell response and it is therefore an important and common cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant recipients.
Enzyme-linked immunosorbent spot (ELISPOT) is an effective method for assessment of the magnitude and the quality of T cell immunity by measuring stimulated antigen-specific T cells.
Their statement read that the findings will also help researchers understand T cell immunity against other viral infections like HIV, hepatitis C and tumours.